HC Wainwright Has Bullish Forecast for NTLA FY2025 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – HC Wainwright increased their FY2025 earnings per share estimates for Intellia Therapeutics in a report released on Monday, November 10th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($3.88) for the year, up from their prior estimate of ($4.38). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q4 2025 earnings at ($0.89) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($3.66) EPS.

A number of other analysts have also issued reports on the company. Royal Bank Of Canada dropped their target price on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Friday, November 7th. Wall Street Zen downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Barclays dropped their price target on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, November 7th. Tudor Pickering set a $14.50 price objective on shares of Intellia Therapeutics in a report on Tuesday, October 28th. Finally, JMP Securities cut their target price on shares of Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating on the stock in a research note on Tuesday, October 28th. Twelve analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $18.25.

Intellia Therapeutics Trading Up 4.6%

NTLA opened at $10.18 on Wednesday. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -2.38 and a beta of 2.44. The company has a fifty day simple moving average of $17.13 and a 200 day simple moving average of $12.56.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.10. The firm had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.Intellia Therapeutics’s quarterly revenue was up 51.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.34) EPS.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, Director William J. Chase purchased 100,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were bought at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the acquisition, the director owned 134,693 shares of the company’s stock, valued at approximately $1,350,970.79. This trade represents a 288.24% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael P. Dube sold 1,871 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the transaction, the chief accounting officer owned 55,266 shares of the company’s stock, valued at $960,523.08. This represents a 3.27% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. lifted its position in Intellia Therapeutics by 51.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock worth $140,000 after purchasing an additional 6,722 shares during the period. Envestnet Asset Management Inc. lifted its holdings in Intellia Therapeutics by 9.7% in the 1st quarter. Envestnet Asset Management Inc. now owns 73,150 shares of the company’s stock valued at $520,000 after acquiring an additional 6,496 shares during the last quarter. CWM LLC boosted its position in shares of Intellia Therapeutics by 904.2% during the 1st quarter. CWM LLC now owns 14,912 shares of the company’s stock valued at $106,000 after purchasing an additional 13,427 shares in the last quarter. Grandfield & Dodd LLC grew its stake in shares of Intellia Therapeutics by 56.4% in the 1st quarter. Grandfield & Dodd LLC now owns 48,645 shares of the company’s stock worth $346,000 after purchasing an additional 17,550 shares during the last quarter. Finally, LMG Wealth Partners LLC grew its stake in shares of Intellia Therapeutics by 28.4% in the 1st quarter. LMG Wealth Partners LLC now owns 14,285 shares of the company’s stock worth $102,000 after purchasing an additional 3,157 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.